Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pp65 DC vaccine for newly-diagnosed glioblastoma
NCT02465268Phase 2Completed
- Sponsor
- University of Florida
- Start
- Aug 2016
- Primary completion
- Nov 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of dendritic cells pulsed with cytomegalovirus pp65 RNA in glioblastoma multiforme (GBM), sponsored by University of Florida. Started Aug 2016; status: completed.
02
Drugs
dendritic cells pulsed with cytomegalovirus pp65 RNA
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02465268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465268.